<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268032</url>
  </required_header>
  <id_info>
    <org_study_id>DVR+T001</org_study_id>
    <nct_id>NCT02268032</nct_id>
  </id_info>
  <brief_title>Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve</brief_title>
  <official_title>Assess the Effect of DHEA or Other Androgenic Agents on Ovarian Reserve Markers in Women With Diminished Ovarian Reserve.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Andromaco S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Andromaco S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of continuous administration of DHEA or other androgenic agents on
      ovarian reserve markers in women with diminished ovarian reserve (ROD), such as antral
      follicle count and AMH concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy women protected from pregnancy by surgical sterilization, with no contraindications
      to use androgen therapy, attending the clinic of IDIMI were are invited to participate.

      Project Objetives :

      The general objective is evaluate pharmacokinetic parameters of three vaginal rings local and
      extended release, containing dehydroepiandrosterone (DHEA), testosterone or association of
      both hormones, compared with oral administration of DHEA and testosterone transdermal in
      women

      Secondary objectives are to assess its effects on the hormonal profile, tolerability and
      incidence of adverse events.

        -  DHEA and/or, testosterone levels

        -  Estradiol, FSH, SHBG, androstenediona, cortisol matinal, IGF1.levels

        -  Tolerability and safety assessment by the use of the vaginal ring.

        -  The incidence of adverse events
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of the association of DHEA plus testosterone over ovarian reserve markers</measure>
    <time_frame>2 months</time_frame>
    <description>Measure a composite of ovarian reserve markers: antral follicle count, antimüllerian hormone (AMH), follicle stimulating hormone (FSH) and estradiol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of sex hormone binding globulin (SHBG), androstenedione, morning cortisol, insulin growth factor 1 (IGF- 1), testosterone and dehydroepiandrosterone.</measure>
    <time_frame>2 months</time_frame>
    <description>Measure a composite of hormones that will be compared before and after hormonal therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess tolerability of using the vaginal ring</measure>
    <time_frame>2 months</time_frame>
    <description>A questionnaire will be used post insertion and post extraction on the vaginal ring to asses tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events per group</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Women</condition>
  <condition>Women With Ovarian Reserve Diminish</condition>
  <arm_group>
    <arm_group_label>Vaginal ring 1 (VRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 women using DHEA (VRD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal ring 2 (VRaA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 women using another androgenic agent (VRaA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal ring 3 (VR2A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 women using fixed combination of 2 androgenic agents (VR2A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA</intervention_name>
    <arm_group_label>Vaginal ring 1 (VRD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Another Androgenic Agent (VRaA)</intervention_name>
    <arm_group_label>Vaginal ring 2 (VRaA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed combination of 2 androgenic agents (VR2A)</intervention_name>
    <arm_group_label>Vaginal ring 3 (VR2A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women between 38 and 45 years of age who have not used hormonal contraceptive methods
             at least for the past two months, or who have been surgically sterilized, with no
             contraindications for androgenic therapy.

          2. Women with preserved menstrual cycles.

          3. Women smoking less than 5 cigarettes daily.

          4. AMH between 0.5-1.1 ng/mL

          5. Total AFC 5-7

        Exclusion Criteria:

          1. Women receiving medications that interact with DHEA metabolism (Anastrozole,
             exemestane, Fulvestrant, Insulin, Letrozole, Tamoxifen, Triazolam).

          2. Women with diabetes mellitus

          3. Women with untreated or decompensated endocrine disorders

          4. Women with a prior history of ovarian surgery or oophorectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariel Fuentes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mother &amp; Child Research Institutute (IDIMI), University of Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viviana Muñoz, Midwife</last_name>
    <phone>+5629770873</phone>
    <email>va.munozl@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Torres, Midwife</last_name>
    <phone>+5629770873</phone>
    <email>torreshandrea@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mother and Health Research Institute (IDIMI), Faculty of Medicine, University of Chile</name>
      <address>
        <city>Santiago</city>
        <state>International</state>
        <zip>7501257</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviana Muñoz, Midwife</last_name>
      <phone>+5629770873</phone>
      <email>va.munozl@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ariel Fuentes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <results_reference>
    <citation>Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause. 2004 Nov-Dec;11(6 Pt 2):749-65. Review.</citation>
    <PMID>15543027</PMID>
  </results_reference>
  <results_reference>
    <citation>Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006 Nov;21(11):2845-9. Epub 2006 Sep 22.</citation>
    <PMID>16997936</PMID>
  </results_reference>
  <results_reference>
    <citation>Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod. 2006 Jul;21(7):1884-93. Epub 2006 Mar 3.</citation>
    <PMID>16517559</PMID>
  </results_reference>
  <results_reference>
    <citation>Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009 Aug;30(5):465-93. doi: 10.1210/er.2009-0006. Epub 2009 Jul 9. Review.</citation>
    <PMID>19589949</PMID>
  </results_reference>
  <results_reference>
    <citation>Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod. 2009 Feb;24(2):349-59. doi: 10.1093/humrep/den428. Epub 2008 Dec 3.</citation>
    <PMID>19054777</PMID>
  </results_reference>
  <results_reference>
    <citation>Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online. 2010 Sep;21(3):360-5. doi: 10.1016/j.rbmo.2010.04.006. Epub 2010 Apr 18.</citation>
    <PMID>20638339</PMID>
  </results_reference>
  <results_reference>
    <citation>Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004379. doi: 10.1002/14651858.CD004379.pub3. Review.</citation>
    <PMID>20091563</PMID>
  </results_reference>
  <results_reference>
    <citation>Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod. 2010 Oct;25(10):2496-500. doi: 10.1093/humrep/deq220. Epub 2010 Aug 21.</citation>
    <PMID>20729538</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormone replacement therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

